Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 49% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
8 authors at 4 institutions in 1 country.
Erandi Velarde de la CruzDepartment of Medicine, Boston Children's Hospital, Boston, MA, United States.
Lingyun WangDepartment of Medicine, Boston Children's Hospital, Boston, MA, United States.
Deepanwita BoseDepartment of Medicine, Boston Children's Hospital, Boston, MA, United States.
Sailaja GangadharaEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Robert L WilsonDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
Rama R AmaraEmory Vaccine Center, Yerkes National Primate Research Center, Emory University, Atlanta, GA, United States.
Pamela A KozlowskiDepartment of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA, United States.
Anna AldoviniDepartment of Medicine, Boston Children's Hospital, Boston, MA, United States.
Boston Children's Hospital · USEmory University · USLouisiana State University Health Sciences Center New Orleans · USHarvard University · US
Funding
B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection - Administrative SupplementUM1AI124436 · NIAID · EMORY UNIVERSITY · PI AMARA, RAMA RAO, HUNTER, ERIC · 2016 to 2021
$42.3M
Nonhuman Primate Reagent ResourceU24AI126683 · NIAID · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI Diogo Magnani · 2016 to 2026
$20.1M
Resource for Nonhuman Primate Cell Depleting AntibodiesR24OD010976 · OD · UNIV OF MASSACHUSETTS MED SCH WORCESTER · PI ENGELMAN, KATHLEEN, MAGNANI, DIOGO · 2012 to 2019
$4.7M
Prophylactic oral vaccination for SIV and SHIV infections and AIDS preventionR01DE026325 · NIDCR · BOSTON CHILDREN'S HOSPITAL · PI ALDOVINI, ANNA · 2016 to 2020
We modified a Sabin Oral Poliovirus Vaccine (OPV) vector to permit secretion of the antigens of interest with the goal of improving anti-HIV Env humoral responses in a SHIV mucosal immunization composed of DNA and recombinant OPVs. We evaluated stimulation of systemic and mucosal cell-mediated and humoral immunity in Rhesus macaques by two regimens, both involving a prime with a SHIV
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Oral Vaccination Approaches for Anti-SHIV Immunity. · full record | OpenQuestion